Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 35

References for PMC Articles for PubMed (Select 21423209)


Ron receptor tyrosine kinase activation confers resistance to tamoxifen in breast cancer cell lines.

McClaine RJ, Marshall AM, Wagh PK, Waltz SE.

Neoplasia. 2010 Aug;12(8):650-8.


Classical and Novel Prognostic Markers for Breast Cancer and their Clinical Significance.

Taneja P, Maglic D, Kai F, Zhu S, Kendig RD, Fry EA, Inoue K.

Clin Med Insights Oncol. 2010 Apr 20;4:15-34.


Targeting Wnt signaling: can we safely eradicate cancer stem cells?

Takahashi-Yanaga F, Kahn M.

Clin Cancer Res. 2010 Jun 15;16(12):3153-62. doi: 10.1158/1078-0432.CCR-09-2943. Epub 2010 Jun 8. Review.


Epithelial-mesenchymal transition in cancer: parallels between normal development and tumor progression.

Micalizzi DS, Farabaugh SM, Ford HL.

J Mammary Gland Biol Neoplasia. 2010 Jun;15(2):117-34. doi: 10.1007/s10911-010-9178-9. Epub 2010 May 19. Review.


Epidermal growth factor receptor regulates beta-catenin location, stability, and transcriptional activity in oral cancer.

Lee CH, Hung HW, Hung PH, Shieh YS.

Mol Cancer. 2010 Mar 19;9:64. doi: 10.1186/1476-4598-9-64.


Key signalling nodes in mammary gland development and cancer: Myc.

Hynes NE, Stoelzle T.

Breast Cancer Res. 2009;11(5):210. doi: 10.1186/bcr2406. Epub . Review.


The Ron receptor tyrosine kinase positively regulates angiogenic chemokine production in prostate cancer cells.

Thobe MN, Gurusamy D, Pathrose P, Waltz SE.

Oncogene. 2010 Jan 14;29(2):214-26. doi: 10.1038/onc.2009.331. Epub 2009 Oct 19.


The Ron receptor tyrosine kinase negatively regulates mammary gland branching morphogenesis.

Meyer SE, Zinser GM, Stuart WD, Pathrose P, Waltz SE.

Dev Biol. 2009 Sep 1;333(1):173-85. doi: 10.1016/j.ydbio.2009.06.028. Epub 2009 Jul 1.


Met induces diverse mammary carcinomas in mice and is associated with human basal breast cancer.

Graveel CR, DeGroot JD, Su Y, Koeman J, Dykema K, Leung S, Snider J, Davies SR, Swiatek PJ, Cottingham S, Watson MA, Ellis MJ, Sigler RE, Furge KA, Vande Woude GF.

Proc Natl Acad Sci U S A. 2009 Aug 4;106(31):12909-14. doi: 10.1073/pnas.0810403106. Epub 2009 Jun 30.


The beta-catenin axis integrates multiple signals downstream from RET/papillary thyroid carcinoma leading to cell proliferation.

Castellone MD, De Falco V, Rao DM, Bellelli R, Muthu M, Basolo F, Fusco A, Gutkind JS, Santoro M.

Cancer Res. 2009 Mar 1;69(5):1867-76. doi: 10.1158/0008-5472.CAN-08-1982. Epub 2009 Feb 17.


beta-catenin gene mutation in invasive ductal breast cancer.

Kizildag S, Zengel B, Vardar E, Sakizli M.

J BUON. 2008 Oct-Dec;13(4):533-6.


A novel RET kinase-beta-catenin signaling pathway contributes to tumorigenesis in thyroid carcinoma.

Gujral TS, van Veelen W, Richardson DS, Myers SM, Meens JA, Acton DS, Duñach M, Elliott BE, Höppener JW, Mulligan LM.

Cancer Res. 2008 Mar 1;68(5):1338-46. doi: 10.1158/0008-5472.CAN-07-6052.


beta-Catenin signaling in biological control and cancer.

Gavert N, Ben-Ze'ev A.

J Cell Biochem. 2007 Nov 1;102(4):820-8. Review.


The macrophage-stimulating protein pathway promotes metastasis in a mouse model for breast cancer and predicts poor prognosis in humans.

Welm AL, Sneddon JB, Taylor C, Nuyten DS, van de Vijver MJ, Hasegawa BH, Bishop JM.

Proc Natl Acad Sci U S A. 2007 May 1;104(18):7570-5. Epub 2007 Apr 24.


Mammary-specific Ron receptor overexpression induces highly metastatic mammary tumors associated with beta-catenin activation.

Zinser GM, Leonis MA, Toney K, Pathrose P, Thobe M, Kader SA, Peace BE, Beauman SR, Collins MH, Waltz SE.

Cancer Res. 2006 Dec 15;66(24):11967-74.


Activation of Wnt/beta-catenin pathway during hepatocyte growth factor-induced hepatomegaly in mice.

Apte U, Zeng G, Muller P, Tan X, Micsenyi A, Cieply B, Dai C, Liu Y, Kaestner KH, Monga SP.

Hepatology. 2006 Oct;44(4):992-1002.


Therapeutic implications of a human neutralizing antibody to the macrophage-stimulating protein receptor tyrosine kinase (RON), a c-MET family member.

O'Toole JM, Rabenau KE, Burns K, Lu D, Mangalampalli V, Balderes P, Covino N, Bassi R, Prewett M, Gottfredsen KJ, Thobe MN, Cheng Y, Li Y, Hicklin DJ, Zhu Z, Waltz SE, Hayman MJ, Ludwig DL, Pereira DS.

Cancer Res. 2006 Sep 15;66(18):9162-70.


Tyrosine residues 654 and 670 in beta-catenin are crucial in regulation of Met-beta-catenin interactions.

Zeng G, Apte U, Micsenyi A, Bell A, Monga SP.

Exp Cell Res. 2006 Nov 1;312(18):3620-30. Epub 2006 Aug 10.


Study of phospho-beta-catenin subcellular distribution in invasive breast carcinomas in relation to their phenotype and the clinical outcome.

Nakopoulou L, Mylona E, Papadaki I, Kavantzas N, Giannopoulou I, Markaki S, Keramopoulos A.

Mod Pathol. 2006 Apr;19(4):556-63.


A physiologic imaging pilot study of breast cancer treated with AZD2171.

Miller KD, Miller M, Mehrotra S, Agarwal B, Mock BH, Zheng QH, Badve S, Hutchins GD, Sledge GW Jr.

Clin Cancer Res. 2006 Jan 1;12(1):281-8.

Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk